Standard of Care Treatment and Therapies for DYRK1A Syndrome
At a Glance
DYRK1A syndrome has no cure, so treatment focuses on each child’s needs. Early speech therapy and communication tools such as AAC, seizure care, physical and occupational therapy, and feeding and nutrition support can improve communication, safety, movement, growth, and independence.
There is currently no cure for DYRK1A syndrome, but early and consistent therapy can significantly improve a child’s ability to communicate, move, and grow [1]. Treatment is “symptomatic,” meaning it focuses on managing the specific challenges your child faces rather than the genetic cause itself [1][2].
Prioritizing Communication
Because severe speech impairment is a hallmark of DYRK1A syndrome, speech-language therapy is a cornerstone of care.
- AAC Intervention: Research shows that only a small number of children (about 20% in one study) develop enough verbal speech to rely on it alone [3]. Most children use a combination of signs and Augmentative and Alternative Communication (AAC) [3].
- High-Tech and Low-Tech Options: AAC can range from simple picture boards to high-tech tablet-based apps that speak for the child [3][4]. Experts recommend introducing these tools early—rather than waiting for speech to fail—to reduce frustration and support brain development [3]. Using AAC does not prevent or suppress spoken-language development and can be used alongside speech therapy; communication access is an ongoing reassessment.
- Motor Speech Support: For children who do speak, therapy often targets apraxia (trouble planning speech movements) and dysarthria (muscle weakness/incoordination) to make their words clearer and more functional [3].
Managing Seizures and Epilepsy
Seizures are common in DYRK1A syndrome, appearing in anywhere from one-third to two-thirds of children [3][5].
- Febrile Seizures: Many children have their first seizure during a fever in infancy [6][7]. While a recognized part of the condition’s early course, fever does not make a seizure benign [7].
- Seizure Safety Plan: Every caregiver needs an active seizure safety plan. Time the seizure, protect the child by placing them on their side, and put nothing in the mouth. Call emergency services if a seizure lasts about five minutes or longer, if repeated seizures occur without recovery, if there are breathing or color changes, or if it is a first seizure.
- Medication: If a child develops epilepsy (repeated seizures), doctors typically find they respond well to standard antiseizure medications (ASMs) [2]. There is no single “best” drug for DYRK1A; your neurologist will choose a medication based on your child’s specific seizure type and age [2].
Physical and Occupational Therapy
Early intervention helps address the unique way children with DYRK1A syndrome move and interact with their world.
- Gait and Balance: Therapy often focuses on helping children manage ataxia (clumsiness) and a broad-based gait (walking with feet wide apart) [5][8]. Goals include improving balance, strengthening core muscles, and potentially using orthotics (braces) if foot alignment is an issue [5][9].
- Muscle Tone: Therapists work to manage hypotonia (floppiness) in infants and monitor for hypertonia (stiffness) or contractures (permanent muscle tightening) as the child grows [1][9].
- Daily Living: Occupational therapy helps children gain independence with fine motor tasks, such as feeding themselves or using a communication device [1][10].
Feeding and Nutritional Support
Many infants with DYRK1A syndrome struggle to gain weight due to feeding difficulties [11].
- Growth Monitoring: Doctors may use specialized growth charts designed specifically for children with DYRK1A syndrome to track their height, weight, and head circumference more accurately than standard charts [12].
- Feeding Therapy and Aspiration Risk: Be alert for signs of aspiration (food or liquid entering the lungs), such as coughing or choking during feeds, wet breathing, or recurrent chest infections. If present, request a clinical swallow evaluation rather than just trying new textures [1][9]. If your child has trouble sucking, swallowing, or shows signs of reflux, a feeding therapist or nutritionist can provide strategies to make mealtime safer.
A Note on Emerging Research
You may hear about research into DYRK1A inhibitors, such as green tea extract (EGCG). EGCG is not an established treatment for DYRK1A haploinsufficiency. Down syndrome is caused by an extra chromosome 21 involving many genes (resulting in too much DYRK1A), not by DYRK1A alone, and those studies do not establish treatment for DYRK1A loss of function [13][14]. In fact, EGCG may be mechanistically inappropriate or harmful in DYRK1A syndrome, and concentrated extracts carry risks of severe liver toxicity and medication interactions [15][16]. Families are strongly advised not to self-treat and to consult a specialist instead.
Common questions in this guide
What treatments are usually used for DYRK1A syndrome?
When should a child with DYRK1A syndrome start using AAC?
When is a seizure an emergency for a child with DYRK1A syndrome?
What therapies can help with walking and coordination in DYRK1A syndrome?
How are feeding and growth problems managed in DYRK1A syndrome?
Do antiseizure medicines work for children with DYRK1A syndrome?
Is green tea extract an established treatment for DYRK1A syndrome?
Get notified when new evidence is published on Neurodevelopmental disorder with microcephaly, impaired language, and gait abnormalities.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
DYRK1A pathogenic variants in two patients with syndromic intellectual disability and a review of the literature.
Meissner LE, Macnamara EF, D'Souza P, et al.
Molecular genetics & genomic medicine 2020; (8(12)):e1544 doi:10.1002/mgg3.1544.
PMID: 33159716 - 2
Clinical course of epilepsy and white matter abnormality linked to a novel DYRK1A variant.
Okazaki T, Yamada H, Matsuura K, et al.
Human genome variation 2021; (8(1)):26 doi:10.1038/s41439-021-00157-7.
PMID: 34253714 - 3
Social motivation a relative strength in DYRK1A syndrome on a background of significant speech and language impairments.
Morison LD, Braden RO, Amor DJ, et al.
European journal of human genetics : EJHG 2022; (30(7)):800-811 doi:10.1038/s41431-022-01079-w.
PMID: 35437318 - 4
A delayed intervention start randomized controlled trial of high- and low-tech communication training approaches for school-age autistic children with co-occurring intellectual disability.
Gilroy SP, McCleery JP, Leader G
Journal of applied behavior analysis 2023; (56(3)):593-606 doi:10.1002/jaba.989.
PMID: 37092868 - 5
DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.
Ji J, Lee H, Argiropoulos B, et al.
European journal of human genetics : EJHG 2015; (23(11)):1473-81 doi:10.1038/ejhg.2015.71.
PMID: 25944381 - 6
Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID.
van Bon BW, Coe BP, Bernier R, et al.
Molecular psychiatry 2016; (21(1)):126-32 doi:10.1038/mp.2015.5.
PMID: 25707398 - 7
DYRK1A mutations in two unrelated patients.
Ruaud L, Mignot C, Guët A, et al.
European journal of medical genetics 2015; (58(3)):168-74.
PMID: 25641759 - 8
Clinical and molecular overlap between nucleotide excision repair (NER) disorders and DYRK1A haploinsufficiency syndrome.
Le May N, Courraud J, Boujelbène I, et al.
Frontiers in neuroscience 2025; (19()):1554093 doi:10.3389/fnins.2025.1554093.
PMID: 40206408 - 9
Case report of novel DYRK1A mutations in 2 individuals with syndromic intellectual disability and a review of the literature.
Luco SM, Pohl D, Sell E, et al.
BMC medical genetics 2016; (17()):15 doi:10.1186/s12881-016-0276-4.
PMID: 26922654 - 10
Interventions for Transition-Age Youth With Disabilities: A Meta-Analysis of Group Design Studies.
Crowley S
American journal on intellectual and developmental disabilities 2022; (127(3)):169-193 doi:10.1352/1944-7558-127.3.169.
PMID: 35443051 - 11
Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.
Bronicki LM, Redin C, Drunat S, et al.
European journal of human genetics : EJHG 2015; (23(11)):1482-7 doi:10.1038/ejhg.2015.29.
PMID: 25920557 - 12
Growth charts in DYRK1A syndrome.
Lanvin PL, Goronflot T, Isidor B, et al.
American journal of medical genetics. Part A 2024; (194(1)):9-16 doi:10.1002/ajmg.a.63412.
PMID: 37740550 - 13
DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment.
De Toma I, Ortega M, Aloy P, et al.
Frontiers in molecular neuroscience 2019; (12()):272 doi:10.3389/fnmol.2019.00272.
PMID: 31803016 - 14
Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Stringer M, Abeysekera I, Thomas J, et al.
Physiology & behavior 2017; (177()):230-241 doi:10.1016/j.physbeh.2017.05.003.
PMID: 28478033 - 15
DYRK1A - a gene dose paradox.
Plećaš A, Gough G, Kunštek S, et al.
Frontiers in cell and developmental biology 2026; (14()):1963992 doi:10.3389/fcell.2026.1963992.
PMID: 42909264 - 16
The role of Goldilocks protein kinase DYRK1A in embryonic development.
Johnson HK, Litovchick LL, Dickinson AJG
Developmental biology 2025; (525()):216-228 doi:10.1016/j.ydbio.2025.06.009.
PMID: 40505942
This page describes supportive treatments and safety planning for children with DYRK1A syndrome for educational purposes only; it does not constitute medical advice. Your child's neurologist and therapy team should tailor care to their needs.